Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The goal of this phase I-II clinical research study is to find the highest safe dose of
XRP9881 and capecitabine that can be given in combination in the treatment of metastatic
breast cancer in patients who have been previously treated by taxanes and anthracyclines. The
safety and effectiveness of this combination will also be studied. Patients participating in
the study will be asked to give additional blood samples to look at the level of study drugs
in the blood.